Inventiva stock, SBF 120 laggard, drops nearly 12%
The Burgundy-based biotech company specializing in fibrotic and metabolic diseases suffers a sharp reversal this Thursday, after a rebound that had propelled it to the top of the index. The decline erases a large portion of the previous day's rebound and brings the stock to its lowest level in several weeks, within an SBF 120 itself down more than 1%.
Inventiva SBF 120 laggard with a decline of nearly 12% during the session
Inventiva falls 11.99% to €2.90 during the session, marking the steepest decline in the SBF 120 this Thursday morning. The stock retreats under selling pressure following a marked rebound on Wednesday, which had temporarily pushed it to the top of the index following the publication of its half-yearly results. Over one month, the decline now reaches 28.4%, while the annual slide exceeds 40%.
The price remains well below its three moving averages: 14.45% below the 20-day MA at €3.39, 22.67% below the 50-day MA at €3.75, and 32.40% below the 200-day MA at €4.29. This positioning illustrates a fundamental downward dynamic that has gradually established itself over several months. The support level at €2.77 is approaching, less than 5% below the current price.
Two analyst ratings maintained at buy amid a cash position under surveillance
The two available analyst ratings remain positive on the stock, despite the revision made by TD Cowen on September 29: the bank lowered its price target from €10 to €9, while maintaining its favorable opinion. KBC Securities for its part maintains a target of €8. These two targets represent respective upside potential of more than 200% and nearly 175% compared to the current price, a gap that primarily reflects the uncertainty surrounding the company rather than a signal.
This uncertainty is directly linked to the clinical calendar. The accounts published on September 28, 2026 highlighted a cash position of €166.1 million as of June 30, strengthened by an equity offering of €103 million and a financing transaction of €75 million announced in June. The company is now awaiting the main results of its pivotal phase 3 NATiV3 study on lanifibranor in MASH, expected in the fourth quarter of 2026; it is around this timeline that the bulk of the risk is concentrated.
